OR WAIT null SECS
Through the agreement, Foamix will have access to $20 million of financing to fund the commercial launches of the topical treatments.
Foamix Pharmaceuticals, a specialty pharmaceutical company based in Israel, announced a long term contract manufacturing and supply agreement with ASM Aerosol-Service, a liquid and semi-liquid product contract manufacturer in Switzerland, for ASM’s AMZEEQ (minocycline), a topical foam for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients, and FMX103 (minocycline), a topical foam for treatment of moderate to severe papulopustular rosacea in adults.
Through the agreement, Foamix will have access to $20 million of financing under its existing credit agreement with Perceptive and OrbiMed to fund the commercial launches of AMZEEQ and, pending FDA approval, FMX103, according to an Oct. 23, 2019 press release.
“This agreement represents another milestone in our overall strategy to bring AMZEEQ to market in January 2020 and to commercialize FMX103 when and if approved by [FDA],” said David Domzalski, CEO of Foamix, in the press release. “Entering into a manufacturing contract with ASM is a critical step in securing our supply chain, which we believe will ensure the availability of supply once we launch AMZEEQ and, if approved, FMX103.”